Introduction {#section1-1076029617734310}
============

Atrial fibrillation (AF) increases the risk of ischemic stroke by 5-fold and is associated with 15% of strokes in all age-groups and 30% in persons older than 80 years.^[@bibr1-1076029617734310]^ Patients with AF-related stroke have higher recurrent risk, morbidity, and mortality when compared to patients with other stroke types.^[@bibr2-1076029617734310]^ Current guidelines emphasize stroke prevention in patients with AF, in the presence of stroke risk factors.^[@bibr3-1076029617734310]^ Effective stroke prevention essentially refers to oral anticoagulation. The use of vitamin K antagonists (VKAs) reduces stroke/systemic embolism by 64% and all-cause mortality by 26%, compared to control or placebo.^[@bibr4-1076029617734310]^ However, the use of VKAs has many limitations, including the need to ensure proper anticoagulation control by regular monitoring, given VKAs' many interactions with drugs and diet.^[@bibr5-1076029617734310]^ As a result, 30% to 50% of patients with AF were undertreated.^[@bibr6-1076029617734310]^ To overcome the limitations of VKAs, the direct oral anticoagulants (DOACs) have been introduced and offer relative efficacy, safety, and convenience compared to VKA therapy.^[@bibr7-1076029617734310]^ The available DOACs, dabigatran, rivaroxaban, apixaban, and edoxaban, were approved by the US Food and Drug Administration in October 2010, November 2011, December 2013, and January 2015, respectively.

Rivaroxaban and apixaban are 2 DOACs whose target specificity is activated factor X (FXa), which is why they are referred to here as xabans.^[@bibr8-1076029617734310][@bibr9-1076029617734310]--[@bibr10-1076029617734310]^ The mechanism of action of rivaroxaban and apixaban is the inhibition of prothrombinase complex-bound and clot-associated FXa, resulting in a reduction of the thrombin burst during the propagation phase of the coagulation cascade. Thrombin is an essential enzyme in the coagulation system and it is also the strongest endogenous platelet agonist.^[@bibr11-1076029617734310]^ Effect of thrombin on platelets is mainly mediated by 2 G-protein-coupled receptors, protease-activated receptor 1 (PAR1) and PAR4.^[@bibr12-1076029617734310]^ Mechanistically, thrombin proteolytically cleaves a part of the extracellular loop of these receptors. It mediates platelet aggregation, calcium mobilization, and platelet shape change, ultimately resulting in activation of the platelet glycoprotein (GP)IIb/IIIa receptor.^[@bibr13-1076029617734310][@bibr14-1076029617734310]--[@bibr15-1076029617734310]^ xabans do not directly affect platelet aggregation induced by collagen or adenosine diphosphate, but by inhibiting FXa, they indirectly decrease clot formation induced by thrombin.^[@bibr16-1076029617734310],[@bibr17-1076029617734310]^ Therefore, the aim of the present study was to assess the effects of xabans on in vitro platelet aggregation in patients with nonvalvular AF.

Materials and Methods {#section2-1076029617734310}
=====================

The local ethical committee of the Jessenius Faculty of Medicine in Martin approved this study (EK 1702/2015). All study participants agreed to participate in the project and signed a written informed consent in accordance with the Declaration of Helsinki.

Rivaroxaban was administered at fixed 15 mg once-daily dose (at 7:00 [am).]{.smallcaps} This study also tested apixaban administered at twice-daily dose of 2.5 or 5 mg (at 7:00 [pm]{.smallcaps} and 7:00 [am]{.smallcaps}). Blood samples were taken before drug dose administration (sample 1, at 7:00 [am]{.smallcaps}) for the assessment of the apixaban or rivaroxaban trough level and 2 hours later (sample 2, at 9:00 [am]{.smallcaps}) for the assessment of the apixaban or rivaroxaban peak level. To be sure that the drug was administered at the right time, we implemented the following measures. First, the drug was administered to the patients by a physician who was involved in this study. Second, treatment with xabans was monitored by anti-Xa assay for rivaroxaban or apixaban according to the manufacturer's instructions. All patients on xabans therapy included in our study were hospitalized in the First Department of Internal Medicine during July and November 2016. We do not have any selection criteria. The study investigators had no influence on drug choice (rivaroxaban or apixaban) or dosage. Concomitant treatment (eg, β-blockers, proton pump inhibitor, and so on) was administered immediately after taking the morning dose of xabans.

Light transmission aggregometry (LTA) was performed using the international protocol for the laboratory investigation of platelet function.^[@bibr18-1076029617734310]^ We wanted to emphasize that testing was performed on patients without any antiplatelet or nonsteroidal anti-inflammatory drugs (10-14 days before measurement) and with normal platelet count (≥150 × 109/L). The antecubital venous blood was collected into tubes containing 3.2% buffered sodium citrate (anticoagulant--blood ratio 1:9) to assess platelet aggregation. Platelet aggregability was tested with platelet-rich plasma using platelet aggregometry (PACKS-4 aggregometer; Helena Laboratories, Beaumont, USA). Blood samples were stimulated with thrombin receptor activating peptide (TRAP; 10 μmoL).

Data are presented as numbers with frequencies for categorical variables and means with standard deviations (SD) for continuous variables. For comparison of the different groups, the closed test principle was used. An overall comparison was performed, followed by pairwise comparison if the results were significant. All tests were 2-tailed, and *P* values \<.05 were considered statistically significant. Data were analyzed with SPSS 21.0.0.0 (SPSS Inc, Chicago, Illinois).

Results {#section3-1076029617734310}
=======

[Table 1](#table1-1076029617734310){ref-type="table"} presents full clinical baseline characteristics of the patients. Forty-one patients with nonvalvular AF were enrolled. The mean age was 74.85 (9.32) years (range: 55-94 years), 22 patients were women, and the mean CHA~2~DS~2~VASc score was 3.83 (1.24). All patients began treatment with apixaban or rivaroxaban as initial anticoagulant treatment. The minimum term use of xabans was 18 days. Apixaban doses were 5 mg (65%) or 2.5 mg (35%) twice daily. The mean apixaban concentration was 66.48 (34.22) ng/mL in sample 1 and 151.56 (41.54) ng/mL in sample 2. Concentrations of rivaroxaban in serum (sample 1) were 45.92 (36.86) ng/mL and 195.53 (96.18) ng/mL 2 hours after administration (sample 2). The TRAP-induced platelet aggregation did not correlate significantly with apixaban or rivaroxaban levels (see [Table 2](#table2-1076029617734310){ref-type="table"}). Through subgroup analysis, we found that apixaban significantly reduced the TRAP-induced platelet aggregation more than rivaroxaban. Subgroup analysis showed a significant reduction in TRAP-induced platelet aggregation after administration of angiotensin-converting enzyme blockers, proton pump inhibitors, and statins (see [Table 3](#table3-1076029617734310){ref-type="table"}).

###### 

Clinical Baseline Characteristics of the Patients.

![](10.1177_1076029617734310-table1)

  Characteristics                                                                              Number of Patients or Value
  -------------------------------------------------------------------------------------------- -----------------------------
  Number of patients                                                                           
   Apixaban                                                                                    20
   Rivaroxaban                                                                                 21
  Age, years, mean (SD); range                                                                 74.85 (9.32); 55-94
   ≤65 years                                                                                   7
   \>65 years                                                                                  34
  Sex                                                                                          
   Male                                                                                        19
   Female                                                                                      22
  Indication                                                                                   
   Atrial fibrillation                                                                         41
    Valvular                                                                                   0
    Nonvalvular                                                                                41
    Paroxysmal                                                                                 16
    Persistent                                                                                 14
    Permanent                                                                                  11
  Dose                                                                                         
   Apixaban 5 mg twice daily                                                                   13
   Apixaban 2.5 mg twice daily                                                                 7
   Rivaroxaban 15 mg once daily                                                                21
  Positive medical history:                                                                    
   Diabetes mellitus                                                                           20
   Arterial hypertension                                                                       41
   Renal disease                                                                               21
   Dialysis, transplant, creatinine \>2.26 mg/dL or \>200 µmol/L                               1
   Liver disease                                                                               10
   Cirrhosis or bilirubin \>2× normal with AST/ALT/AP \>3× normal                              0
   Cerebral stroke/transient ischemic attack history                                           13
   Coronary artery disease                                                                     11
    One vessel                                                                                 5
    Two vessels                                                                                6
   History of pulmonary embolism                                                               1
   Myocardial infarction history                                                               13
  Body mass index, kg/m^2^                                                                     
   Normal weight (18.5-24.9)                                                                   17
   Overweight (25.0-29.9)                                                                      8
   Obese (30.0-39.9)                                                                           16
  Ischemic heart disease---Classification according to the New York heart association (NYHA)   
   I                                                                                           0
   II                                                                                          25
   III                                                                                         15
   IV                                                                                          1
  CHA~2~DS~2~VASc score, mean (SD); range                                                      3.83 (1.24); 2-7
   2                                                                                           5
   3                                                                                           13
   4                                                                                           13
   5                                                                                           5
   6                                                                                           4
   7                                                                                           1
  HAS-BLED score, mean (SD); range                                                             1.76 (0.89); 1-5
   1                                                                                           18
   2                                                                                           18
   3                                                                                           3
   4                                                                                           1
   5                                                                                           1
  Platelets × 10^9^/L, range × 10^9^/L                                                         240 (158-321)
  Creatinine, μmol/L, mean (SD)                                                                113.66 (36.24)
   Male                                                                                        
    Normal (55-100)                                                                            5
    Elevated (\>100)                                                                           14
   Female                                                                                      
    Normal (44-95)                                                                             13
    Elevated (\>95)                                                                            9
  ALT, μkat/L, mean (SD)                                                                       0.39 (0.38)
   Normal (0.1-0.6)                                                                            35
   Elevated (\>0.6)                                                                            6
  AST, μkat/L, mean (SD)                                                                       0.42 (0.33)
   Normal (0.1-0.6)                                                                            37
   Elevated (\>0.6)                                                                            4
  Gamma glutamyltransferase (γGT), μkat/L, mean (SD)                                           1.12 (1.54)
   Normal (0.07-0.63)                                                                          24
   Elevated (\>0.63)                                                                           17
  Drugs                                                                                        
   β-Blockers                                                                                  28
   Calcium channel blockers                                                                    11
   Angiotensin-converting enzyme blockers                                                      23
   Angiotensin II receptor antagonists                                                         10
   Antiplatelet drugs                                                                          0
   Proton pump inhibitor                                                                       30
   Statins                                                                                     16

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; SD, standard deviation.

###### 

Correlation Between TRAP-Induced Platelet Aggregation and Antifactor Xa (Rivaroxaban) and Antifactor Xa (Apixaban) in Samples 1 and 2.^a^

![](10.1177_1076029617734310-table2)

                                                                                                            Antifactor Xa (Sample 1)   TRAP-Induced Platelet Aggregation (Sample 1)   
  --------------------------------------------------------------------------------------------------------- -------------------------- ---------------------------------------------- --------
  \(A\) Correlation between TRAP-induced platelet aggregation and antifactor Xa (rivaroxaban) in sample 1                                                                             
  TRAP-induced platelet aggregation (sample 1)                                                              Pearson correlation        1                                              −0.317
  Significance (2 tailed)                                                                                                              0.162                                          
  Antifactor IIa (sample 1)                                                                                 Pearson correlation        −0.317                                         1
  Significance (2 tailed)                                                                                   0.162                                                                     
  \(B\) Correlation between TRAP-induced platelet aggregation and antifactor Xa (rivaroxaban) in sample 2                                                                             
  TRAP-induced platelet aggregation (sample 2)                                                              Pearson correlation:       1                                              −0.312
  Significance (2 tailed)                                                                                                              0.169                                          
  Antifactor IIa (sample 2)                                                                                 Pearson correlation:       −0.312                                         1
  Significance (2 tailed)                                                                                   0.169                                                                     
  \(C\) Correlation between TRAP-induced platelet aggregation and anti-factor Xa (apixaban) in sample 1                                                                               
  TRAP-induced platelet aggregation (sample 1)                                                              Pearson correlation        1                                              0.328
                                                                                                            Significance (2 tailed)                                                   0.158
  Antifactor IIa (sample 1)                                                                                 Pearson correlation        0.328                                          1
  Significance (2 tailed)                                                                                   0.158                                                                     
  \(D\) Correlation between TRAP-induced platelet aggregation and antifactor Xa (apixaban) in sample 2                                                                                
  TRAP-induced platelet aggregation (sample 2)                                                              Pearson correlation        1                                              0.134
  Significance (2 tailed)                                                                                                              0.573                                          
  Antifactor IIa (sample 2)                                                                                 Pearson correlation:       0.134                                          1
  Significance (2 tailed)                                                                                   0.573                                                                     

Abbreviation: TRAP, thrombin receptor activating peptide.

^a^Correlation is significant at the 0.01 level (2 tailed).

###### 

Subgroup Analysis.

![](10.1177_1076029617734310-table3)

  Subgroup Analysis                                                                     TRAP-Induced Platelet Aggregation^a^       *P* Value
  ------------------------------------------------------------------------------------- ------------------------------------------ ------------
  Rivaroxaban vs apixaban                                                               Sample 1: 58.81% (9.7%) vs 53.35% (6.1%)   *P =* .051
  Sample 2: 33.81% (11.4%) vs 25.0% (13.2%)                                             P = .03                                    
  Rivaroxaban vs apixaban 5 mg twice daily                                              Sample 1: 58.81% (9.7%) vs 55.46% (5.7%)   *P =* .07
  Sample 2: 33.81% (11.4%) vs 23.85% (11.8%)                                            P = .02                                    
  Rivaroxaban vs apixaban 2.5 mg twice daily                                            Sample 1: 58.81% (9.7%) vs 54.42% (5.1%)   *P =* .06
  Sample 2: 33.81% (11.4%) vs 27.14% (16.2%)                                            P = .023                                   
  ≤65 years vs \>65 years                                                               Sample 1: 96.5% (7.3%) vs 88.4% (10.7%)    *P =* .80
  Sample 2: 82.5% (11.3%) vs 78.6% (14.0%)                                              *P =* .64                                  
  Diabetes mellitus vs without diabetes mellitus                                        Sample 1: 55.8% (8.6%) vs 56.5% (8.7%)     *P =* .80
  Sample 2: 30.5% (11.4%) vs 28.6% (14.4%)                                              *P =* .64                                  
  With a history of renal disease vs without a history of renal disease                 Sample 1: 53.3% (6.9%) vs 59.1% (9.2%)     *P =* .51
  Sample 2: 28.3% (12.3%) vs 30.8% (13.7%)                                              *P =* .54                                  
  With a history of liver disease vs without a history of liver disease                 Sample 1: 53.3% (6.9%) vs 59.1% (9.2%)     *P =* .51
  Sample 2: 28.3% (12.3%) vs 30.8% (13.7%)                                              *P =* .54                                  
  With coronary artery disease vs without coronary artery disease                       Sample 1: 54.6% (7.8%) vs 56.7% (8.9%)     *P =* .47
  Sample 2: 32.3% (16.0%) vs 28.5% (11.7%)                                              *P =* .41                                  
  With myocardial infarction history vs without myocardial infarction history           Sample 1: 56.7% (5.6%) vs 58.2% (8.9%)     *P =* .21
  Sample 2: 26.5% (12.6%) vs 30.9% (13.0%)                                              *P =* .32                                  
  Normal weight vs overweight and obese                                                 Sample 1: 56.1% (7.4%) vs 56.2% (9.4%)     *P =* .99
  Sample 2: 28.4% (13.6%) vs 30.3% (12.7%)                                              *P =* .63                                  
  Overweight vs obese                                                                   Sample 1: 57.7% (11.5%) vs 55.3% (8.3%)    *P =* .56
  Sample 2: 28.0% (16.8%) vs 31.7% (9.8%)                                               *P =* .50                                  
  Normal creatinine level vs elevated creatinine level                                  Sample 1: 57.4% (7.7%) vs 54.5% (8.9%)     *P =* .28
  Sample 2: 28.4% (11.0%) vs 29.5% (14.1%)                                              *P =* .79                                  
  Normal AST level vs elevated AST level                                                Sample 1: 55.9% (8.8%) vs 58.5% (5.4%)     *P =* .57
  Sample 2: 30.1% (12.6%) vs 24.0% (16.0%)                                              *P =* .38                                  
  Normal ALT level vs elevated ALT level                                                Sample 1: 55.7% (8.7%) vs 59.0% (7.1%)     *P =* .38
  Sample 2: 29.4% (12.5%) vs 30.3% (16.4%)                                              *P =* .87                                  
  Normal γGT level vs elevated γGT level                                                Sample 1: 55.8% (8.5%) vs 56.7% (8.7%)     *P =* .73
  Sample 2: 27.6% (13.0%) vs 32.2% (12.7%)                                              *P =* .27                                  
  β-Blockers vs no β-blockers                                                           Sample 1: 55.0% (7.0%) vs 58.7% (11.1%)    *P =* .2
  Sample 2: 29.9% (13.4%) vs 28.8% (12.2%)                                              *P =* .8                                   
  Calcium channel blockers vs no calcium channel blockers                               Sample 1: 57.1% (8.4%) vs 55.8% (8.7%)     *P =* .67
  Sample 2: 26.5% (12.3%) vs 30.6 (13.2%)                                               *P =* .37                                  
  Angiotensin-converting enzyme blockers vs no angiotensin-converting enzyme blockers   Sample 1: 54.87% (9.1%) vs 57.8% (7.7%)    *P =* .28
  Sample 2: 25.65% (12.4%) vs 34.4% (12.1%)                                             P = .03                                    
  Angiotensin II receptor antagonists vs no angiotensin II receptor antagonists         Sample 1: 55.3% (7.0%) vs 56.4% (9.1%)     *P =* .72
  Sample 2: 36.9% (11.5%) vs 27.1 (12.6%)                                               P = .04                                    
  Proton pump inhibitor vs no proton pump inhibitor                                     Sample 1: 56.0% (8.4%) vs 56.5% (9.2%)     *P =* .86
  Sample 2: 32.2% (12.6%) vs 22.2% (11.3%)                                              P = .03                                    
  Statins vs no statins                                                                 Sample 1: 57.1% (6.7%) vs 55.5% (9.6%)     *P =* .6
  Sample 2: 34.9% (11.2%) vs 26.1% (13.0%)                                              P = .03                                    

Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; γGT, gamma glutamyltransferase; TRAP, thrombin receptor activating peptide.

^a^Values are mean (standard deviation) for continuous variables.

As shown in [Figure 1](#fig1-1076029617734310){ref-type="fig"}, the TRAP-induced platelet aggregation by LTA was significantly reduced in sample 2 compared to sample 1 (56.15% \[8.53%\] vs 29.51% \[12.9%\]; *P =* .000). Aggregation results for each patient are shown in [Figure 2](#fig2-1076029617734310){ref-type="fig"}.

![Results of thrombin receptor activating peptide (TRAP)-induced platelet aggregation.](10.1177_1076029617734310-fig1){#fig1-1076029617734310}

![Aggregation results for each patient.](10.1177_1076029617734310-fig2){#fig2-1076029617734310}

Discussion {#section4-1076029617734310}
==========

To our knowledge, this is the first prospective comprehensive study to test whether the xabans affect TRAP-induced platelet aggregation. This study aimed to analyze the influence of the DOACs apixaban and rivaroxaban on platelet function. Thrombin is a key protein in the cascade of fibrin clot formation and also a potent inducer of platelet aggregation.^[@bibr18-1076029617734310][@bibr19-1076029617734310][@bibr20-1076029617734310]--[@bibr21-1076029617734310]^ The FXa inhibitors potently and selectively inhibit thrombin formation.^[@bibr22-1076029617734310]^ Thrombin is capable of activating platelets, which is mediated primarily by the hydrolysis of a G-protein-coupled receptor on the platelet membrane, referred to as PAR-1 and a second receptor (PAR-4) that expresses a lower sensitivity to thrombin.^[@bibr23-1076029617734310]^ Probably, low concentration of thrombin (blocked FXa cannot activate thrombin) is unable to cleave and activate PAR-1. However, the effects of xabans on platelet aggregation are still not fully understood.

This single-center study quantifies platelet aggregation in 41 patients treated with xabans by LTA. The TRAP-induced platelet aggregation was significantly lower 2 hours after administration of xabans compared to baseline value (56.15% \[8.53%\] vs 29.51% \[12.9%\]). Thus, xabans reduce platelet aggregation by 53% at the time of maximum plasma concentration. However, patients with higher doses of apixaban showed higher TRAP-induced platelet aggregation ([Table 3](#table3-1076029617734310){ref-type="table"}) with dose-dependent characteristics. Nevertheless, no direct association between the apixaban plasma level and TRAP-induced aggregation was found in this study ([Table 2](#table2-1076029617734310){ref-type="table"}). This indicates that the enhanced TRAP-induced platelet aggregation is not necessarily an immediate effect of apixaban but may be explained by the duration of chronic apixaban therapy. In addition, TRAP-induced aggregation should bypass any indirect effect of xabans on thrombin generation. Thus, our data indicate that the TRAP-induced platelet aggregation is enhanced by a chronic, indirect inhibition of thrombin. This might be due to changes in the expression of PAR-1 receptor on the platelets. The same results were observed in study by Olivier et al and Renda et al.^[@bibr24-1076029617734310],[@bibr25-1076029617734310]^

No significant differences were found in the patients with a history of renal or liver disease, diabetes, coronary artery disease, myocardial infarction, and so on (see [Table 3](#table3-1076029617734310){ref-type="table"}). It seems that the concomitant use of angiotensin-converting enzyme blockers, proton pump inhibitors, and statins reduces the efficiency of xabans. So far, these interactions have not been seen in any other study.

Our findings could have some important clinical implications because platelet aggregation and coagulation cascade are affected at the same time. The situation could be more worse during concomitant administration of antiplatelet or anticoagulant agents. Moreover, concomitant use of angiotensin-converting enzyme blockers, proton pump inhibitors, and statins reduces the efficiency of xabans. But on the other side, it reduces the impact of xabans on platelet aggregation.

There were several limitations in our study. The small number of participants may have limited the ability to detect small drug effects on platelet function. Second, this study was not powered for clinical outcome. Therefore, it cannot be concluded that, for example, combination of antiplatelet therapy and xabans is not safe. Third, platelet aggregability is greatly affected by preanalytical issues and therefore interpretation of platelet hyperaggregability is potentially accordingly adversely influenced.

Conclusion {#section5-1076029617734310}
==========

In conclusion, our study showed significant effect of xabans on platelet aggregability. Moreover, concomitant use of angiotensin-converting enzyme blockers, proton pump inhibitors, and statins reduces the efficiency of xabans. Future, larger investigations are required to confirm our hypothesis-generating work and correlate them with thrombotic and bleeding clinical events.
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